SCHEMBL6478451

SCHEMBL6478451

CN1C(=O)N(Cc2ccc(C(=O)O)cc2)S(=O)(=O)c2cc(C#CCc3ccccc3)ncc21

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 5/20 0.44
SLC22A8 Q8TCC7 1/20 0.44
HDAC1 Q13547 4/20 0.35
HDAC2 Q92769 4/20 0.35
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
RECQL P46063 1/20 0.34
PLEC Q15149 1/20 0.34
SAE1 Q9UBE0 1/20 0.34
UBA2 Q9UBT2 1/20 0.34
AGTR1 P30556 4/20 0.34
AGTR2 P50052 2/20 0.34
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8355360 0.84 MMP13 (0.52) MMP13SLC22A8HDAC1HDAC2KDM4E
SCHEMBL6268084 0.79 MMP13 (0.43) MMP13SLC22A8MAPTMEN1HPGD
SCHEMBL6517128 0.78 MEN1 (0.43) HDAC1HDAC2MAPTMEN1HPGD
SCHEMBL8358996 0.75 CA12 (0.40) MMP13SLC22A8CA12CA9HSD11B1
SCHEMBL6478179 0.75 MMP13 (0.42) MMP13SLC22A8MAPTMEN1HPGD
SCHEMBL6485954 0.74 MMP13 (0.41) MMP13SLC22A8HDAC1HDAC2HPGD
SCHEMBL8359060 0.74 MMP13 (0.43) MMP13SLC22A8HDAC1HDAC2MAPT
SCHEMBL6489891 0.73 MMP13 (0.43) MMP13SLC22A8HDAC1HDAC2MEN1
SCHEMBL21624598 0.72 HDAC1 (0.48) HDAC1HDAC2MAPTMEN1KMT2A
SCHEMBL6255601 0.72 MMP13 (0.74) MMP13SLC22A8HDAC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849648-B2 Phenylene alkyne matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-01 US disclosed
US-20040034086-A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib ROARK WILLIAM HOWARD (US) 2004-02-19 US disclosed
US-20040034085-A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib ROARK WILLIAM HOWARD (US) 2004-02-19 US disclosed
US-20040019055-A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib ROARK WILLIAM HOWARD (US) 2004-01-29 US disclosed
US-20030144274-A1 Alkyne matrix metalloproteinase inhibitors BUNKER AMY MAE (US) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019055-A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib MMP13, MMP11, MMP10 MMP13 1/4885SLC22A8 155/4885HDAC1 630/4885
US-20040034086-A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib MMP11, MMP13, MMP10 MMP13 2/4885SLC22A8 255/4885HDAC1 435/4885
US-20030144274-A1 Alkyne matrix metalloproteinase inhibitors MMP11, MMP13, MMP3 MMP13 2/4885SLC22A8 1147/4885HDAC1 209/4885
US-20040034085-A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib MMP11, MMP13, MMP10 MMP13 2/4885SLC22A8 147/4885HDAC1 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.